[1] |
Marks J, Jenkins PA, Tsukamura M. Mycobacterium szulgai-a new pathogen. Tubercle, 1972, 53(3): 210-214. doi: 10.1016/0041-3879(72)90018-9.
doi: 10.1016/0041-3879(72)90018-9
|
[2] |
Martín-Casabona N, Bahrmand AR, Bennedsen J, et al. Non-tuberculous mycobacteria: patterns of isolation. A multi-country retrospective survey. Int J Tuberc Lung Dis, 2004, 8(10): 1186-1193.
pmid: 15527150
|
[3] |
刘盛盛, 唐神结. 《非结核分枝杆菌病诊断与治疗指南(2020年版)》解读. 结核与肺部疾病杂志, 2021, 2 (2): 108-115. doi: 10.3969/j.issn.2096-8493.2021.02.004.
doi: 10.3969/j.issn.2096-8493.2021.02.004
|
[4] |
吴玲, 刘志辉, 雷杰, 等.广州地区分枝杆菌菌株库资源分析. 国际医药卫生导报, 2017, 23(15): 2322-2325, 2382. doi: 10.3760/cma.j.issn.1007-1245.2017.15.003.
doi: 10.3760/cma.j.issn.1007-1245.2017.15.003
|
[5] |
罗春明, 邹桂敏, 刘国标, 等. 广州市2003—2012年非结核分枝杆菌菌种鉴定结果分析. 结核病与肺部健康杂志, 2014, 3 (1): 15-20. doi: 10.3969/j.issn.2095-3755.2014.01.004.
doi: 10.3969/j.issn.2095-3755.2014.01.004
|
[6] |
王小坡, 陈志明, 宋昊, 等.皮肤苏尔加分枝杆菌感染一例. 中华皮肤科杂志, 2016, 49(10): 724-726. doi: 10.3760/cma.j.issn.0412-4030.2016.10.011.
doi: 10.3760/cma.j.issn.0412-4030.2016.10.011
|
[7] |
刘敏, 李明俊, 余庆, 等. 重庆市HIV与NTM双重感染患者的菌种分布及耐药情况. 中国防痨杂志, 2021, 43(5): 501-505. doi: 10.3969/j.issn.1000-6621.2021.05.016.
doi: 10.3969/j.issn.1000-6621.2021.05.016
|
[8] |
中华医学会结核病学分会.非结核分枝杆菌病诊断与治疗指南(2020年版). 中华结核和呼吸杂志, 2020, 43(11): 918-946. doi: 10.3760/cma.j.cn112147-20200508-00570.
doi: 10.3760/cma.j.cn112147-20200508-00570
|
[9] |
Li G, Pang H, Guo Q, et al. Antimicrobial susceptibility and MIC distribution of 41 drugs against clinical isolates from China and reference strains of nontuberculous mycobacteria. Int J Antimicrob Agents, 2017, 49(3): 364-374. doi: 10.1016/j.ijantimicag.2016.10.024.
doi: 10.1016/j.ijantimicag.2016.10.024
URL
|
[10] |
Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med, 2007, 175(4): 367-416. doi: 10.1164/rccm.200604-571ST.
doi: 10.1164/rccm.200604-571ST
URL
|
[11] |
van Ingen J, Boeree MJ, de Lange WC, et al. Clinical relevance of Mycobacterium szulgai in The Netherlands. Clin Infect Dis, 2008, 46(8): 1200-1205. doi: 10.1086/529443.
doi: 10.1086/529443
URL
|
[12] |
Yoo H, Jeon K, Kim SY, et al. Clinical significance of Mycobacterium szulgai isolates from respiratory specimens. Scand J Infect Dis, 2014, 46(3): 169-174. doi: 10.3109/00365548.2013.861607.
doi: 10.3109/00365548.2013.861607
URL
|
[13] |
Pang H, Jiang Y, Wan K. Drug Susceptibility of 33 Reference Strains of Slowly Growing Mycobacteria to 19 Antimicrobial Agents. Biomed Res Int, 2017, 2017: 1584658. doi: 10.1155/2017/1584658.
doi: 10.1155/2017/1584658
|
[14] |
肖士林, 赵秀芹, 刘志广, 等. 5种中国罕见慢速生长非结核分枝杆菌标准株及临床分离株的药物敏感性分析. 疾病监测, 2020, 35(5): 435-441. doi: 10.3784/j.issn.1003-9961.2020.05.015.
doi: 10.3784/j.issn.1003-9961.2020.05.015
|
[15] |
Gido RDS, Wojciechowski AL, Bajwa RP. Pulmonary infection with Mycobacterium szulgai: A case report. SAGE Open Med Case Rep, 2019, 7: 2050313X18823448. doi: 10.1177/2050313X18823448.
doi: 10.1177/2050313X18823448
|